Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Karyopharm Therapeutics ( (KPTI) ) has issued an update.
Karyopharm Therapeutics announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer, and Treasurer, effective January 3, 2025. Macomber, with extensive experience in financial roles within the biotechnology and pharmaceutical industries, will also serve as the company’s principal financial officer, succeeding Kristin Abate. Her compensation package includes a base salary, performance-based bonus, and inducement awards, reflecting the company’s strategic commitment to enhancing its leadership and financial management capabilities.
More about Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a company operating in the biotechnology industry, focusing on the development and commercialization of novel drugs for the treatment of cancer and other major diseases.
Average Trading Volume: 922,696
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $85.34M
See more insights into KPTI stock on TipRanks’ Stock Analysis page.
